Is Palvella Therapeutics, Inc (PVLA) overvalued? · $1.64B cap
Palvella Therapeutics, Inc (PVLA) is a biotechnology company listed on NASDAQ.
This page asks whether Palvella Therapeutics, Inc (PVLA) looks expensive on cached numbers — not a short thesis.
Latest reported PVLA revenue for 2024-09-30 was $0. Net income was -$13.5M. PVLA currently screens at market cap $1.64B.
PVLA currently screens at market cap $1.64B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PVLA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PVLA stock page for the full model, not this heading.
Not investment advice.